Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Cottu, P; Ring, A; Abdel-Razeq, H; Marchetti, P; Cardoso, F; Bofill, JS; Martin, M; Menon-Singh, L; Wu, JW; De Laurentiis, M.

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

BREAST. 2022; 62: 75-83 Nº de citas: 8 [doi:10.1016/j.breast.2022.01.016]

Duca, M; Lim, DWT; Subbiah, V; Takahashi, S; Sarantopoulos, J; Varga, A; D'Alessio, JA; Abrams, T; Sheng, Q; Tan, EY; Rosa, MS; Gonzalez-Maffe, J; Sand-Dejmek, J; Fabre, C; Martin, M.

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

MOLECULAR CANCER THERAPEUTICS. 2022; 21(4): 625-634 Nº de citas: 5 [doi:10.1158/1535-7163.MCT-21-0652]

Verso, M; Agnelli, G; Munoz, A; Connors, JM; Sanchez, O; Huisman, M; Brenner, B; Gussoni, G; Cohen, AT; Becattini, C.

Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

EUROPEAN JOURNAL OF CANCER. 2022; 165: 136-145 Nº de citas: 10 [doi:10.1016/j.ejca.2022.01.023]

Blum, JL; Laird, AD; Litton, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Martin, M; Roche, HH; Lee, KH; Goodwin, A; Chen, Y; Lanzalone, S; Chelliserry, J; Czibere, A; Hopkins, JF; Albacker, LA; Mina, LA.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

CLINICAL CANCER RESEARCH. 2022; 28(7): 1383-1390 Nº de citas: 12 [doi:10.1158/1078-0432.CCR-21-2080]

Valderrama, BP; Gonzalez-del-Alba, A; Morales-Barrera, R; Fernandez, IP; Vazquez, S; Diaz, CC; Domenech, M; Calvo, OF; Lista, AGD; Arija, JAA.

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 613-624 Nº de citas: 9 [doi:10.1007/s12094-022-02815-w]

Majem, M; de las Penas, R; Virizuela, JA; Cabezon-Gutierrez, L; Cruz, P; Lopez-Castro, R; Mendez, M; Mondejar, R; Munoz, MD; Escobar, Y.

SEOM clinical guideline emesis (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 712-723 Nº de citas: 6 [doi:10.1007/s12094-022-02802-1]

Felip, E; Moreno, V; Morgensztern, D; Curigliano, G; Rutkowski, P; Trigo, JM; Calvo, A; Kowalski, D; Cortinovis, D; Plummer, R; Maio, M; Ascierto, PA; Vladimirov, VI; Cervantes, A; Zudaire, E; Hazra, A; T'jollyn, H; Bandyopadhyay, N; Greger, JG; Attiyeh, E; Xie, H; Calvo, E.

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2022; 89(4): 499-514 Nº de citas: 7 [doi:10.1007/s00280-022-04414-6]

Echavarria, I; Galindo, JRC; Corral, J; Tain, MPD; Carrasco, FH; Gonzalez-Cruz, VI; Mielgo-Rubio, X; Quintanar, T; Corredor, CR; Segura, PP.

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 724-732 Nº de citas: 9 [doi:10.1007/s12094-022-02800-3]

Elez, E; Gomez-Espana, MA; Gravalos, C; Garcia-Alfonso, P; Ortiz-Morales, MJ; Losa, F; Diaz, IA; Grana, B; Toledano-Fonseca, M; Valladares-Ayerbes, M; Polo, E; Salgado, M; De Castro, EM; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, J; Riesco, MD; Rodriguez-Ariza, A; Aranda, E.

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

BRITISH JOURNAL OF CANCER. 2022; 126(6): 874-880 Nº de citas: 5 [doi:10.1038/s41416-021-01638-w]

Garcia-Saenz, JA; Martinez-Janez, N; Cubedo, R; Jerez, Y; Lahuerta, A; Gonzalez-Santiago, S; Ferrer, N; Ramos, M; Alonso-Romero, JL; Anton, A; Carrasco, E; Chen, JJ; Neuwirth, R; Galinsky, K; Vincent, S; Leonard, EJ; Slamon, D.

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

CLINICAL CANCER RESEARCH. 2022; 28(6): 1107-1116 Nº de citas: 9 [doi:10.1158/1078-0432.CCR-21-2652]

Alsar, JS; de la Tabla, AGO; Moran, LO; Martin, AJM.

Treatment modalities in cancer-associated venous thromboembolism (VTE)

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2022; 35(1): Nº de citas: 2 [doi:10.1016/j.beha.2022.101354]

Lopez-Tarruella, S; Echavarria, I; Jerez, Y; Herrero, B; Gamez, S; Martin, M.

How we treat HR-positive, HER2-negative early breast cancer

Future Oncology. 2022; 18(8): 1003-1022 Nº de citas: 11 [doi:10.2217/fon-2021-0668]

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(3): 483-494 Nº de citas: 31 [doi:10.1007/s12094-021-02708-4]

Ledermann, JA; Zurawski, B; Raspagliesi, F; De Giorgi, U; Arija, JA; Marin, MR; Lisyanskaya, A; Poka, RL; Markowska, J; Cebotaru, C; Herraez, AC; Colombo, N; Kutarska, E; Hall, M; Jacobs, A; Ahrens-Fath, I; Baumeister, H; Zurlo, A; Sehouli, J.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

Esmo Open. 2022; 7(1): Nº de citas: 8 [doi:10.1016/j.esmoop.2021.100311]

Calvo, A; Gonzalez-Hidalgo, M; Terleira, A; Fernandez, N; Portoles, A.

Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers

Journal of Clinical Medicine. 2022; 11(4): Nº de citas: 1 [doi:10.3390/jcm11041141]

Schoffski, P; Tan, DSW; Martin, M; Ochoa-de-Olza, M; Sarantopoulos, J; Carvajal, RD; Kyi, C; Esaki, T; Prawira, A; Akerley, W; De Braud, F; Hui, RN; Zhang, T; Soo, RA; Maur, M; Weickhardt, A; Krauss, J; Deschler-Baier, B; Lau, A; Samant, TS; Longmire, T; Chowdhury, NR; Sabatos-Peyton, CA; Patel, N; Ramesh, R; Hu, TC; Carion, A; Gusenleitner, D; Yerramilli-Rao, P; Askoxylakis, V; Kwak, EL; Hong, DS.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) +/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Journal for ImmunoTherapy of Cancer. 2022; 10(2): Nº de citas: 127 [doi:10.1136/jitc-2021-003776]

Muino, CB; Martin, M; del Monte-Millan, M; Garcia-Saenz, JA; Lopez-Tarruella, S.

HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Cancers. 2022; 14(3): Nº de citas: 2 [doi:10.3390/cancers14030512]

Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL; PALLAS groups and investigators.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(3): 282-293 Nº de citas: 167 [doi:10.1200/JCO.21.02554]